Paris

• Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel Recruiting
  2023-505530-10-00 6 2022-09-14 Multiple Myeloma
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
• Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD) Recruiting
  2024-511899-32-00 10 2022-08-31 Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
• Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing An … Recruiting
  2024-515243-37-00 11 2022-08-21 Kidney Transplantation BKV infection
• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple M … Recruiting
  2023-506247-42-00 3 2022-08-17 Relapsed/Refractory Multiple Myeloma
• An outpatient study to learn if Staccato Alprazolam is safe and effective when treating long seizures in children ≥12 years of age and adult … Recruiting
  2024-510950-29-00 5 2022-07-21 Stereotypical prolonged seizure
• LANdiolol MIcrocirculatory effects during Septic chOc (MILANOS) Recruiting
  2024-512757-24-00 5 2022-07-18 Patients with microcirculatory abnormalities during septic shock
• VAC-WARTS Recruiting
  2024-513671-40-00 5 2022-06-29 HPV vaccine
• Preventive effect of Clopidogrel on the systemic sclerosis development risk Recruiting
  2024-511005-39-00 10 2022-06-22 Raynaud phenomenon
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin … Recruiting
  2023-505347-38-00 9 2022-06-13 B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
• A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o … Recruiting
  2024-516331-27-00 3 2022-06-10 Participants with BRAF and/or NRAS mutation positive tumors
• Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma … Recruiting
  2024-513986-38-00 4 2022-06-01 Locally advanced or metastatic papillary cell carcinoma (PRCC)
• A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting
  2024-515354-24-00 9 2022-05-18 Low risk myelodysplastic syndrom without RS having failed or being ine
• Fecal Microbiota Transplantation in the prevention of complications after allogeneic hematopoietic stem cell transplantation for hematologic … Recruiting
  2024-512969-14-01 4 2022-05-02 Patient who underwent Allogeneic hematopoietic stem cell transplantati
• A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte … Recruiting
  2024-515945-40-00 10 2022-05-02 Non small cell lung cancer
• A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting
  2023-509743-27-00 4 2022-04-29 Systemic sclerosis associated with interstitial lung disease
• PEMBROCABOSARC : Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas Recruiting
  2023-509496-16-00 4 2022-04-21 Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, o
• FI-3, Fidelia Recruiting
  2024-518243-38-00 5 2022-04-20 Fecal incontinence in female and male patients
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• A phase I study of the mesothelin x cd47 antibody NI-1801, as single agent and in combination with anti-pd-1 antibody, or with paclitaxel al … Recruiting
  2024-517752-35-00 1 2022-04-04 Advanced, metastatic, or recurrent solid mesothelin-expressing maligna
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participan … Recruiting
  2023-504129-38-00 4 2022-03-31 Fibrodysplasia Ossificans Progressiva
• Study of BGB-11417 in Patients with Myeloid Malignancies Recruiting
  2023-508881-14-00 9 2022-03-21 Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic sy
• EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam th … Recruiting
  2022-502434-10-00 4 2022-02-22 Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a typ

Showing 1,129–1,152 of 2,286 trials